These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 29861152)

  • 1. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
    Murry L; Gerleman B; Urick B; Urmie J
    J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing changes in third-party gross margin for a single community pharmacy.
    Urick BY; Urmie JM; Doucette WR; McDonough RP
    J Am Pharm Assoc (2003); 2014; 54(1):27-34. PubMed ID: 24362541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a change in third party reimbursement rate on prescription gross margin.
    Ganther JM; Kreling DH
    J Am Pharm Assoc (Wash); 1999; 39(3):346-52. PubMed ID: 10363461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
    Carroll NV
    J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of costs to dispense prescriptions in independently owned, closed-door long-term care pharmacies.
    Carroll NV; Rupp MT; Holdford DA
    J Manag Care Spec Pharm; 2014 Mar; 20(3):291-300. PubMed ID: 24564809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of insurance type with costs of dispensed drugs.
    Mott DA; Kreling DH
    Inquiry; 1998; 35(1):23-35. PubMed ID: 9597015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating pharmacy level prescription drug acquisition costs for third-party reimbursement.
    Kreling DH; Kirk KW
    Med Care; 1986 Jul; 24(7):590-600. PubMed ID: 3523065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negotiating with third party payers: one community pharmacy's experience.
    Fridy K; DeHart RM; Monk-Tutor MR
    J Am Pharm Assoc (Wash); 2002; 42(5):780-8. PubMed ID: 12269712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community pharmacy and mail order cost and utilization for 90-day maintenance medication prescriptions.
    Khandelwal N; Duncan I; Rubinstein E; Ahmed T; Pegus C
    J Manag Care Pharm; 2012 Apr; 18(3):247-55. PubMed ID: 22468733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans.
    Johnsrud M; Lawson KA; Shepherd MD
    J Manag Care Pharm; 2007 Mar; 13(2):122-34. PubMed ID: 17330973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case study using descriptive analysis to estimate hidden costs in processing third party prescriptions.
    Herrier RN; Spencer JR; Davis CD
    J Am Pharm Assoc (Wash); 2000; 40(5):658-65. PubMed ID: 11029847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of a $4 generic drug program in a 340B pharmacy.
    Bright DR; Adams AJ; Akala FO; Lengel AJ; Martin SJ; Powers MF
    Am J Health Syst Pharm; 2010 Jun; 67(11):929-31. PubMed ID: 20484217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing.
    Bazalo G; Weiss RC
    Consult Pharm; 2012 Apr; 27(4):269-73. PubMed ID: 22498986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults.
    Pauly NJ; Brown JD
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1162-70. PubMed ID: 26679965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profitability, third-party reimbursement, and access to community pharmacies.
    Carroll NV; Miederhoff PA; Waters LW
    Clin Ther; 1996; 18(4):703-15; discussion 702. PubMed ID: 8879898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Undocumented source of pharmacy benefit manager revenue.
    Siracuse MV; Clark BE; Garis RI
    Am J Health Syst Pharm; 2008 Mar; 65(6):552-7. PubMed ID: 18319501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of prescription reimbursement methodologies in Japan and the United States.
    Akaho E; MacLaughlin EJ; Takeuchi Y
    J Am Pharm Assoc (2003); 2003; 43(4):519-26. PubMed ID: 12952317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.